Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Forbion
AddedFeb 13, 2024
UpdatedJul 2, 2026
Forbion

Forbion

Operating

FCPM III Services B.V.: A Netherlands-based venture capital firm.

Location
Naarden, North Holland, NL
Founded
2006
Firm
Analysis
Compare
Portfolio
Employees
Website

Investments

Memento Medicines
Memento Medicines
Series A

Total Raised

$93M

Rounds

1

Series A$93MJune 2026
Rampart Bioscience
Rampart Bioscience

Total Raised

$85M

Rounds

1

Series A$85MOctober 2023
Aiolos Bio
Aiolos Bio
Acquired

Total Raised

$245M

Rounds

1

Series A$245MOctober 2023
Mariana Oncology
Mariana Oncology

Total Raised

$250M

Rounds

2

Series B$175MSeptember 2023
Armgo Pharma
Armgo Pharma

Total Raised

$36M

Rounds

2

Series B$35MDecember 2021
Rectify Pharmaceuticals
Rectify Pharmaceuticals

Total Raised

$100M

Rounds

1

Series A$100MOctober 2021
Numab
Numab

Total Raised

$122M

Rounds

3

Series C$100MMay 2021
CoviCept Therapeutics
CoviCept Therapeutics

Total Raised

$2.3M

Rounds

1

Seed$2.3MJanuary 2021
Hookipa Pharma
Hookipa Pharma
Public

Total Raised

$284.8M

Rounds

10

Series C$60MDecember 2017
Series B$10MDecember 2016
Series B$20MNovember 2013
Series A$7MOctober 2011
Realeve
Realeve

Total Raised

$136.2M

Rounds

6

Series D$43.2MJune 2015
Series D$38MMay 2015
Insmed
Insmed
Public

Total Raised

$3B

Rounds

13

Post Ipo EquityMarch 2015
bluebird bio
bluebird bio
Public

Total Raised

$3.4B

Rounds

17

Series D$60MJuly 2012
Series C$30MApril 2011
Series B$35MMarch 2010
argenx
argenx
Public

Total Raised

$3.4B

Rounds

11

Series B$32.5MDecember 2011
Series A$4.5MFebruary 2010
Series A$13.6MSeptember 2009
Acorda Therapeutics
Acorda Therapeutics
Public

Total Raised

$151.6M

Rounds

12

Series B$55.3MMay 2003